Progenity
Lynne Powell is the Chief Executive Officer of Druggability Technologies (DRGT).
Ms. Powell was appointed to the board in February 2019. She brings more than 25 years of cross-functional and global experience. She is currently CEO of Druggability Technologies (DRGT) and prior to that was Chief Commercial Officer at BioCryst Pharmaceuticals. She spent 17 years of her career at CSL in roles of increasing responsibility, starting as Head of Clinical Research for plasma products and concluding as SVP, General Manager, Commercial Operations, North America. Ms. Powell has launched multiple products globally and in the U.S. She also held positions within Glaxo Wellcome’s commercial strategy and clinical research organizations in the UK. She received an MBA from Monash University in Australia.
This person is not in the org chart
This person is not in any offices
Progenity
Progenity helps patients and their families Prepare for Life, with medically relevant health information starting before conception, through pregnancy and adulthood. Using our highly-complex molecular diagnostic testing, healthcare providers can access the most advanced genomic technology to guide patient care at critical life stages.